Halozyme Therapeutics (HALO) : The consensus on Halozyme Therapeutics (HALO) based on 4 analyst recommendation on the company stock is 1.75, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Halozyme Therapeutics (HALO).
Halozyme Therapeutics (HALO) : Currently there are 3 street experts covering Halozyme Therapeutics (HALO) stock. The most bullish and bearish price target for the stock is $16 and $7 respectively for the short term. The average price target of all the analysts comes to $12.58. The estimated standard deviation from the target is $5.08.
For the current week, the company shares have a recommendation consensus of Buy.
Halozyme Therapeutics (NASDAQ:HALO): The stock opened at $10.32 and touched an intraday high of $10.58 on Wednesday. During the day, the stock corrected to an intraday low of $10.32, however, the bulls stepped in and pushed the price higher to close in the green at $10.58 with a gain of 2.72% for the day. The total traded volume for the day was 1,018,725. The stock had closed at $10.3 in the previous trading session.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.